Cardiologists support Califf remaining as FDA commissioner in Trump administration
Leading cardiologists hope that Robert Califf, MD, remains as FDA commissioner during Donald Trump’s tenure as President, Reuters reports.
The Senate confirmed Califf as commissioner in February. Califf, a cardiologist and founder of the Duke Clinical Research Institute, joined the FDA in February 2015 and was nominated as commissioner that September.
Califf plans on submitting his resignation from the FDA, which Reuters notes is part of the presidential transition protocol. It is unclear if Trump will accept the resignation or will choose to keep Califf in his current position. However, a few cardiologists told Reuters that Califf has done a good job in his short time with the FDA.
"I think he has a fresh approach and I personally am very hopeful that the new administration will be supportive of his continuing on as FDA commissioner," Mary Walsh, MD, a heart failure specialist and incoming president of the American College of Cardiology, told Reuters.
Earlier this week, Trump appointed Tom Price, MD, as the head of the Department of Health and Human Services. Price is an orthopedic surgeon and Congressman from Georgia who has been a vocal critic the Patient Protection and Affordable Care Act.
Read the full article below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.